1. Market Research
  2. > Healthcare Market Trends

EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

  • December 2015
  • 69 pages
  • GlobalData
Report ID: 3606786

Summary

Table of Contents

Search Inside

EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

Summary

RSV is a common cause of pediatric respiratory infections, and virtually all children will have been infected by the virus by the age of two years. Also, RSV is recognized as an important cause of respiratory illness in adults. The majority of RSV infections present as mild upper respiratory illnesses that often self-resolve within two weeks, although about 1% of cases develop serious lower respiratory complications requiring hospitalization. In older adults, RSV can result in significant morbidity and mortality, and is easily transmissible in living facilities, such as nursing homes. Children under the age of two years and adults over 64 years of age, with certain health conditions, are most at risk for severe RSV infections, and it is therefore recommended that they receive prophylactic treatment.

In each of the 7MM, GlobalData epidemiologists determined that the prophylactic RSV population in 2014, which includes the preterm infant (less than 37 weeks gestational age) population that survived to 2 years of age, the population of infants with neonatal chronic lung disease (CLD), the population of children with congenital respiratory or neuromuscular diseases that compromise respiratory function, the population of children with hemodynamically significant congenital heart disease, and the population of third-trimester pregnant women, was highest for the US, followed by the 5EU (France, Germany, Italy, Spain, and UK) and Japan. This trend was also seen in the hospitalized RSV population, where the US had the highest number of confirmed and estimated RSV hospitalized cases in 2014, followed by the 5EU and Japan.

GlobalData epidemiologists provide a well-rounded, evidence-based historical trend analysis and population forecast for the RSV prophylactic and hospitalized populations. This analysis covered all at-risk groups that are recommended for RSV prophylactic treatment. Each population, including the hospitalized population, was also segmented by ages (0 years, 1 year, and 2 years) and by sex, thereby providing a granular visualization of the RSV prophylactic and hospitalized market in the 7MM. Furthermore, the forecast is based on an in-depth analysis of a comprehensive set of factors that may impact the RSV prophylactic and hospitalized populations. These factors include trends in population changes, births, preterm births, infant mortality, and the disease incidence, prevalence, and mortality.

Scope

- The Respiratory Syncytial Virus (RSV) Infection EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for RSV infection in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the for the pediatric population hospitalized due to RSV infection (hospitalized population), in addition to the pediatric and adult populations that are most at risk for severe RSV infection and are therefore eligible to receive prophylactic treatment (prophylactic population) in these markets.
- The RSV epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The RSV EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global RSV market.
- Quantify patient populations in the global RSV market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for RSV prophylactics and therapeutics in each of the markets covered.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Medical Supplies Market by Type (Diagnostic, Dialysis, Wound Care, Inhalation, Infection Control, Infusion, Intubation, PPE), Application (Anesthesia, Radiology, Sterilization) & End User (Hospital, Clinic, Nursing Home) - Global Forecast to 2021

  • $ 5650
  • Industry report
  • March 2017
  • by MarketsandMarkets

The medical supplies market is expected to reach USD 136.63 billion by 2021 from USD 98.33 billion in 2016, at a CAGR of 6.8% during the forecast period. Factors such as rising number of surgeries, increasing ...

EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025

  • $ 3995
  • Industry report
  • April 2017
  • by GlobalData

EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025 Summary Cystic Fibrosis (CF) is an inherited disorder that affects the cells that produce mucus, sweat and digestive juices, and also causes ...

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Germany

  • $ 1995
  • Industry report
  • May 2017
  • by GlobalData

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Germany Summary Germany has a mature healthcare market based on its high healthcare expenditure and pharmaceutical production. The increasingly ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.